Sanskar Jain posted on LinkedIn that the team had made the tough decision to close Entvin.
SourceEntvin is building AI agents specifically designed to support regulatory teams in the life sciences industry. Our platform leverages AI to streamline workflows, automate complex tasks, and enhance efficiency throughout the regulatory process. By focusing on the unique needs of regulatory teams,
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Entvin was a Y Combinator-backed AI startup for pharma and life-sciences regulatory workflows. It built regulatory intelligence and compliance products focused on labeling, promotional review, document search, and a multi-agency API, and Sanskar Jain announced in March 2026 that the company would close.
Primary product
AI agents and a Global Regulatory Intelligence API for pharma/life-sciences regulatory teams
Founded
2022
Headquarters
128 King St, San Francisco, CA 94107, USA
Team size
1-10
Industry
Software Development
Sub-industry
B2B healthcare IT / regulatory technology for life sciences
Offices
0 jobs at Entvin
Check back later for new openings
Business model
Founders
Co-Founder
Investors
Founder-led and small, with an official site describing a young team (average age 23) and a strong emphasis on compliance, security, and serving global pharma markets from India and the US.
Pricing
Not publicly disclosed; appears to be enterprise/demo-based
Differentiators
Technology
Customers
Competitors
Estimated revenue
₹0–₹10 Cr (public India-entity revenue band, FY ended 2025-03-31)
Sanskar Jain posted on LinkedIn that the team had made the tough decision to close Entvin.
SourceLinkedIn · Mar 2026
Founder Sanskar Jain announced that Entvin would close after the startup journey that began in 2022.
IndiaMedToday · Apr 2025
Covered the company’s out-of-beta launch and funding, framing Entvin as a pharma and life-sciences AI provider.
Indian Startup News · Apr 2025
Summarized the startup’s funding and platform, noting AI automation for FDA regulatory workflows and the company’s founders.
Express Pharma · Apr 2025
Reported the funding and described Entvin’s product as AI for regulatory compliance and FDA drug-approval workflows.
Business Standard · Mar 2025
Reported Entvin’s first funding round and said the money would be used to expand AI capabilities and customer acquisition.